• Consensus Rating: Buy
  • Consensus Price Target: $6.67
  • Forecasted Upside: 51.86%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.39
▼ -0.16 (-3.52%)

This chart shows the closing price for BVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bioventus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BVS

Analyst Price Target is $6.67
▲ +51.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bioventus in the last 3 months. The average price target is $6.67, with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 51.86% upside from the last price of $4.39.

This chart shows the closing price for BVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Bioventus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$3.66 ➝ $7.00Low
12/7/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$7.00Low
8/9/2023Craig HallumUpgradeHold ➝ Buy$4.00 ➝ $6.00Low
4/3/2023Craig HallumLower TargetHold$10.00 ➝ $5.00Low
11/22/2022Craig HallumDowngradeBuy ➝ Hold$10.00Low
11/10/2022Morgan StanleyLower TargetOverweight$11.00 ➝ $5.00Low
11/9/2022Craig HallumLower Target$25.00 ➝ $10.00Low
11/9/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$18.00 ➝ $6.00Low
11/9/2022JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightLow
10/11/2022Morgan StanleyLower TargetOverweight$12.00 ➝ $11.00Low
8/12/2022Morgan StanleyBoost TargetOverweight$11.00 ➝ $12.00Low
3/21/2022The Goldman Sachs GroupLower TargetNeutral$19.00 ➝ $17.00High
3/15/2022Craig HallumInitiated CoverageBuy$30.00Medium
3/11/2022Morgan StanleyLower TargetOverweight$20.00 ➝ $18.00Low
11/15/2021Morgan StanleyInitiated CoverageOverweight$20.00Low
11/9/2021JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Medium
7/1/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$20.00 ➝ $19.00Low
4/19/2021Morgan StanleyBoost TargetOverweight$18.00 ➝ $19.00Low
3/8/2021JPMorgan Chase & Co.Initiated CoverageOverweight$17.00High
3/8/2021Morgan StanleyInitiated CoverageOverweight$18.00High
3/8/2021The Goldman Sachs GroupInitiated CoverageBuy$19.00Medium
(Data available from 2/22/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/23/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/23/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Bioventus logo
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $4.39
Low: $4.31
High: $4.60

50 Day Range

MA: $4.83
Low: $4.33
High: $5.34

52 Week Range

Now: $4.39
Low: $0.80
High: $5.54

Volume

141,206 shs

Average Volume

134,109 shs

Market Capitalization

$345.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Bioventus?

The following Wall Street sell-side analysts have issued reports on Bioventus in the last twelve months: Canaccord Genuity Group Inc., and Craig Hallum.
View the latest analyst ratings for BVS.

What is the current price target for Bioventus?

3 Wall Street analysts have set twelve-month price targets for Bioventus in the last year. Their average twelve-month price target is $6.67, suggesting a possible upside of 51.9%. Canaccord Genuity Group Inc. has the highest price target set, predicting BVS will reach $7.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $6.00 for Bioventus in the next year.
View the latest price targets for BVS.

What is the current consensus analyst rating for Bioventus?

Bioventus currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BVS will outperform the market and that investors should add to their positions of Bioventus.
View the latest ratings for BVS.

What other companies compete with Bioventus?

How do I contact Bioventus' investor relations team?

Bioventus' physical mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The company's listed phone number is 919-474-6700 and its investor relations email address is [email protected]. The official website for Bioventus is www.bioventus.com. Learn More about contacing Bioventus investor relations.